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Introduction: This phase I/II study evaluated the safety and anti-
tumor effect of the combination of erlotinib with cixutumumab, a
recombinant fully humanized anti-insulin-like growth factor-1 re-
ceptor IgG1 monoclonal antibody, in advanced non-small cell lung
cancer (NSCLC).
Methods: Patients with advanced NSCLC were treated in an initial
safety-lead and drop-down cohorts using erlotinib 150 mg/d with
cixutumumab 6 or 5 mg/kg on days 1, 8, 15, and 22 in 28-day cycles
(cohorts 1 and 2). Emerging pharmacokinetic data led to an addi-
tional cohort (3  3 design) with cixutumumab at 15 mg/kg on day
1 in 21-day cycles (cohort 3).
Results: Eighteen patients entered the study (6 at 6 mg/kg, 8 at 5
mg/kg, and 4 at 15 mg/kg), with median age of 65 years. Four of six
patients at 6 mg/kg experienced dose-limiting toxicities (DLTs),
whereas at 5 mg/kg, one of eight patients experienced DLT but three
of eight patients still required a dose delay during cycle 1. At 15
mg/kg every 21 days, two of four patients experienced DLTs. In all
cohorts, DLTs were either G3 rash or fatigue. Five patients had
stable disease as best response and 14 patients had progressive
disease. The median progression-free survival was 39 days (range
21–432 days). Biomarkers analyses showed a trend toward better
progression-free survival seen with higher free baseline insulin-like
growth factor-1 levels as seen with other insulin-like growth fac-
tor-1R inhibitors.
Conclusions: The combinations of cixutumumab at 6 mg/kg every
7 days and 15 mg/kg every 21 days and full-dose erlotinib are not
tolerable in unselected patients with NSCLC, as measured by DLT.
Cixutumumab at 5 mg/kg every 7 days was tolerable per DLT, but
dose delays were common. Efficacy in unselected patients with
NSCLC seems to be low.
Key Words: Non-small cell lung cancer, IGF1R monoclonal anti-
body, EGFR, Metastatic disease.
(J Thorac Oncol. 2012;7: 419–426)
Lung cancer causes more than 150,000 deaths annually inthe United States.1 Epidermal growth factor receptor ty-
rosine kinase inhibitors (EGFR-TKIs) produce responses in
patients with non-small cell lung cancer (NSCLC) with
EGFR-activating mutations; however, all responders eventu-
ally develop resistance, most commonly because of the emer-
gence of a secondary T790M mutation or mesenchymal-epithe-
lial transition factor (cMET) amplification.2–4 Responses in
EGFR wild-type (EGFR-WT) patients also occur but are rare.5
EGFR-TKIs in unselected patients produce improvements in the
second- and third-line setting in progression-free survival (PFS)
and overall survival (OS) compared with placebo, although the
gains are modest.6
In vitro and in vivo studies have implicated the insulin-
like growth factor receptor (IGF-1R), its ligands IGF I and II,
and its related downstream signaling in the development and
progression of cancer.7 Furthermore, the IGF-1R pathway is
implicated as an alternate possible cause of acquired resis-
tance to EGFR-targeted therapy.8,9 Preclinical work demon-
strates that the combination of an IGF-1R inhibitor with an
EGFR-TKI is synergistic in both NSCLC cancer cell lines
that are EGFR-WT and those with mutations in EGFR exons
19 and 21 (EGFR mutation [MT]).10–15
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Cixutumumab (previously IMC-A12; Imclone; Bridge-
water, NJ) is a fully humanized recombinant IgG1/ mono-
clonal antibody with high affinity to the extracellular domain
of IGF-1R with a mean effective concentration of 0.04
nmol/liter, acting as an antagonist of the IGF-I and IGF-II
ligand binding.16 In vitro, cixutumumab treatment induced
apoptosis in sensitive human tumor cell lines and elicited
both tumor growth inhibition and tumor regression across a
broad range of human tumor xenograft models.16 In combi-
nation with EGFR-TKI therapy, cixutumumab showed in-
creased cytoxicity compared with either agent alone in cell
lines and in xenografts.16
Cixutumumab monotherapy, administered intravenously
(IV) every 7 days, is tolerated at doses of up to 10 mg/kg.17
In a phase II trial of 10 mg/kg of IV cixutumumab every 7
days in pretreated patients with chemotherapy refractory
advanced colon cancer, there were few grades 3 and 4 side
effects attributable to the drug, with asymptomatic hypergly-
cemia the most frequent drug-related adverse event (AE).17
The mean terminal elimination half-life of cixutumumab is
148 hours, with trough concentrations above those shown
effective in xenograft models (data on file, Imclone). In a
subsequent phase I study, cixutumumab was shown to be
tolerable up to and including 20 mg/kg when given every 21
days, although these data were not available until midway
through accrual for this clinical trial (data on file, Imclone).
The primary objectives of this study were to explore the
safety and efficacy of the combination of cixutumumab with
full-dose erlotinib, before planned expansion into a random-
ized phase II study comparing full-dose erlotinib with the
combination.
PATIENTS AND METHODS
Patient Selection
Patients with histologically or cytologically docu-
mented locally advanced or metastatic NSCLC, age older
than or equal to 18 years, and those who had progressed on or
after receiving platinum-containing chemotherapy were eli-
gible. A later amendment allowed the enrollment of patients
with EGFR-MTs who were untreated. Other criteria included
Eastern Cooperative Oncology Group performance status
2; life expectancy 3 months; presence of evaluable or
measurable disease as defined by the RECIST (version 1.0);
fasting serum glucose less than 120 mg/dL; and adequate
hematopoietic, hepatic, and renal function. Exclusion criteria
included previous exposure to other EGFR or IGF-1R inhib-
itors; chemotherapy within five half-lives of the agent or 28
days if the half-life was unknown or was a monoclonal
antibody; radiotherapy within 28 days; major surgery within
4 months of the study; ongoing previous treatment-related
side effects/AEs that were grade 2; known brain metastases
unless adequately treated and stable off anticonvulsants and
steroids; pregnancy; and poorly controlled diabetes mellitus
or other uncontrolled intercurrent illness.
The protocol was approved and monitored by all local
institutional review boards. All patients provided written
consent before enrollment.
Study Design and Drug Dosing and
Administration
Patients were enrolled at two institutions into one of the
three cohorts (Figure 1). To assess safety and tolerability, the
initial safety-lead and drop-down cohort used erlotinib 150
mg orally daily with cixutumumab 6 mg/kg (cohort 1) or 5
mg/kg (cohort 2) IV on days 1, 8, 15, and 22 in 28-day cycles.
Tolerability required the completion of one cycle in 8 of 10
patients without dose-limiting toxicity (DLT). Emerging
pharmacokinetic data related to 21-day dosing of cixutu-
mumab led to an amendment and enrollment of a third cohort
with erlotinib 150 mg orally daily with cixutumumab 15
mg/kg IV in 21-day cycles (cohort 3). In this cohort, for
toxicity and feasibility assessment, a standard 3  3 phase I
design was used. At least three patients were required to have
completed one cycle for dose escalation to occur to a planned
cohort 4 (cixutumumab 20 mg/kg IV in 21-day cycles). If
there was one DLT among the first three patients, an addi-
tional three patients were enrolled at the same dose level. If
two DLTs were observed in up to six patients, then dosing at
that level was stopped. The highest tolerated dose regimen
was to be declared the maximum tolerated dose (MTD).
DLT was defined as any treatment delay of 7 days
because of any drug-related toxicity within cycle 1, or any
nonhematological toxicity grade 3 within cycle 1, exclud-
ing rash, diarrhea, nausea, hyperglycemia, hypocalcemia,
hypokalemia, hypomagnesemia, hyponatremia, hypophos-
phatemia, or hypercholesterolemia if controllable within 7
days of holding drug, and no dose reductions occurred. For
both erlotinib and cixutumumab, dose intensity (%) for each
patient was calculated by the amount of drug delivered (mg)
FIGURE 1. Dose cohorts in the
phase I trial.
Weickhardt et al. Journal of Thoracic Oncology • Volume 7, Number 2, February 2012
Copyright © 2012 by the International Association for the Study of Lung Cancer420
divided by the proposed dose delivered (mg) over the dura-
tion they were on study, accounting also for protocol-defined
dose reductions if there was more than 10% change in weight
during treatment.
Cixutumumab was supplied in sterile 250 mg (50 ml)
single-use vials by the Division of Cancer Treatment and
Diagnosis, National Cancer Institute, under a collaborative
agreement between Imclone Systems and the Division of
Cancer Treatment and Diagnosis. Erlotinib was commercially
available (OSI Pharmaceuticals, Farmingdale, NY).
Dose Modification
Dose modification of cixutumumab and erlotinib was
allowed according to the protocol. In the event of grade 3 or
4 DLT, both cixutumumab and erlotinib were held until the
toxicity resolved to grades 0 and 1 (or baseline grade if higher
than grade 1). Patients with greater than a 3-week delay in
treatment were removed from study unless the delay was
deemed by the principal investigator to be unrelated to study
drug and the patient had not experienced clinical progression
of disease. Individual dose modification of cixutumumab and
erlotinib was allowed and performed to the next lowest dose
cohort at investigator discretion. If a patient discontinued
from cixutumumab because of cixutumumab-related toxici-
ties, erlotinib could continue if appropriate.
Safety and Efficacy Assessments
Patients were evaluated with history, physical exami-
nation, vital signs, and blood tests weekly through cycle 1 and
on day 1 of each subsequent cycle. Incidence and severity of
AEs were collected at each study visit and graded according
to National Cancer Institute Common Toxicity Criteria for
Adverse Events version 3. Patients were evaluable for cohort
dose escalation/de-escalation decision making either if they
experienced DLTs in cycle 1 or if they had completed 24 of
the planned 28 days (85%) dosing of erlotinib and three of the
four planned days of weekly dosing of cixutumumab (75%)
in cycle 1 in cohorts 1 and 2 in the absence of DLTs. In cohort
3, patients were evaluable for tolerability if they had com-
pleted 18 days (85%) dosing of erlotinib and had received the
planned day 1 dose of cixutumumab.
Baseline evaluations and radiologic evaluations were
conducted within 4 weeks of study entry. Disease was as-
sessed after every second cycle, with response evaluated
according to the RECIST criteria (version 1.0). Patients were
considered evaluable for objective response if they had mea-
surable disease at baseline, had received at least one dose of
study related therapy, and had a second scan.
PFS was defined from first dose of drug until time of
progression (as measured by time of computed tomogra-
phy [CT] assessment by RECIST demonstrating progres-
sion) or death.
Biomarker Assessment
EGFR-MT analysis was performed where possible
from archived tumor specimens with either bidirectional
sequencing of polymerase chain reaction-amplified DNA
(Roswell Park, Buffalo, NY) or performed through the on-site
Clinical Laboratory Improvement Amendments-certified Col-
orado Molecular Correlates Laboratory.18
Free IGF-1 in the pretreatment-collected serum was
measured using an enzyme-linked immunosorbent assay kit
from Beckman-Coulter Diagnostic System Laboratories
(Webster, TX, Cat# DSL-10-9400). This kit requests ethyl-
enediaminetetraacetic acid plasma samples; however, only
serum samples were collected and used in this study. Follow-
ing the kit’s instructions, no dilution of samples resulted in
poor recovery of the standard exogenously added to a patient
sample and low free IGF-1 values for the patient samples,
suggesting an inhibitory effect within the sample. Therefore,
samples were diluted 1:2 in the zero standard buffer, which
resulted in accurate recovery of the spiked standard and
higher levels of free IGF-1. Further dilutions resulted in no
change of the rank order of the specimens. The concentration
of free IGF-1 reported accounts for the dilution and repre-
sents the concentration within the serum sample.
In addition, archived patient paraffin-embedded tumor
blocks were retrieved where possible, and serum was collected
for pharmacokinetic assays at cycle 1 on day 8 and cycle 2 on
day 1. Supplemental materials (http://links.lww.com/JTO/A199)
include the methods used for silver in situ hybridization assay
and fluorescent in situ hybridization assay for insulin growth
factor receptor (IGFR) and immunohistochemical assessment
of IGFR1 expression.
Statistical Analyses
Descriptive statistics summarized the demographics,
safety data, and efficacy outcomes. Visual representation of
PFS, response, and free IGF-1 levels and PFS was performed
on Prism 5.0 software (Graphpad Software, La Jolla, CA).
Kaplan-Meier curves were generated for time to progression
within wild-type and mutant EGFR groups, respectively. Cox
proportional hazards regression was used to obtain hazard
ratio estimates for the EGFR-mutant group versus the WT
group. Statistical analyses were performed using SAS/BASE
and SAS/STAT software, version 9.2 of the SAS System for
Windows (SAS Institute Inc., Cary, NC).
RESULTS
Patient Characteristics and Trial Overview
Between December 2008 and October 2010, 18 patients
were enrolled across cohorts 1 to 3. Because of DLT issues,
cohort 4 was not explored (see below). Because of concerns
about the achievable dose intensity at the MTD and the
apparent low efficacy in unselected patients with NSCLC (see
subsequent sections), in conjunction with similar concerns
arising with other IGF-1R inhibitors in combination with
erlotinib, the expansion part of the trial beyond the dose
escalation phase was cancelled. The characteristics of the
enrolled patients are listed in Table 1.
Safety
The most frequent AEs were fatigue (72%), acne-
iform rash (56%), diarrhea (50%), anorexia (28%), and
nausea (28%; Table 2). The majority of these were grade 1
or 2 severity. Four patients in cohort 1 experienced DLTs
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(three with grade 3 fatigue and one with grade 3 acneiform
rash, which failed to resolve within 7 days to grade 1
severity on holding the drug), and this dose level in the
q7-dosing regimen was declared nontolerated. One patient
in cohort 2 experienced a DLT (grade 3 acneiform rash,
which failed to resolve within 7 days to grade 1 severity
on holding the drug), and this dose level was declared the
MTD for the every 7 day-dosing regimen. There were two
patients in cohort 3 who experienced a DLT (one with
grade 3 fatigue and one with grade 3 acneiform rash that
failed to resolve within 7 days to grade 1 severity on
holding the drug), and this dose level in the every 21
day-dosing regimen was also declared nontolerated. Only
three patients developed hyperglycemia (all grade 2 sever-
ity); none required treatment.
Three patients, all from cohort 2, withdrew from the
study. One patient withdrew after 1 cycle because of a grade
2 infusion reaction to cixutumumab. One patient with an
EGFR-MT withdrew consent after eight cycles while re-
sponding to therapy to have resection of oligometastatic
disease, and one patient with an EGFR-MT withdrew consent
after nine cycles while responding to therapy because of
patient preference.
Dose Modifications
Fourteen patients (78%) had a delay in treatment or
dose modification while on study (Table 2). The most com-
mon reasons for delay/dose modification were fatigue (five
patients) and rash (five patients). In cohort 1, the mean dose
intensity of cixutumumab was 72% and of erlotinib was 73%.
In cohort 1, five of six patients (83%) required a dose
reduction in the first cycle. In cohort 2, the mean dose
intensity of cixutumumab was 88% and of erlotinib was 78%.
In cohort 2, three of eight (38%) patients required a dose
reduction in the first cycle. In cohort 3, the mean dose
intensity of cixutumumab was 95% and of erlotinib was 79%
and two of four (50%) patients required a dose reduction in
the first cycle. Seventeen patients (94%) maintained the
two-drug combination until progression; one patient received
one cycle of erlotinib alone before progressing after eight
cycles.
Antitumor Activity
All 18 patients were evaluable for response (Table 3;
Figure 2). The median PFS was 39 days (range 21–432
days). Of the 18 patients, 5 patients achieved stable disease
and 13 patients had progressive disease. There were no
TABLE 1. Patient Demographics and Clinical Characteristics
All Patients
(N  18)
Cohort 1
Cixutumumab,
6 mg/kg IV q7
(N  6)
Cohort 2
Cixutumumab,
5 mg/kg IV q7
(N  8)
Cohort 3
Cixutumumab,
15 mg/kg IV q21
(N  4)
Gender
Male 8 4 2 2
Female 10 2 6 2
Age, median (minimum–
maximum), yr
65 (48–77) 67 (48–77) 66 (58–71) 59 (50–67)
Race
White 14 6 5 3
Others 4 0 3 1
Ever smokers 14 3 7 4
ECOG performance status
0 5 2 1 2
1 13 4 7 2
Prior chemotherapy (no. of
regimens)
0 1 0 1 0
1 5 4 1 0
2 4 1 3 0
3 8 1 3 4
Prior radiotherapy 6 2 2 2
Prior surgery 4 1 2 1
Tumor types
Nonsquamous 16 5 7 4
Squamous 2 1 1 0
EGFR status
EGFR mutation (19–21) 3 1 2 0
EGFR wild type 13 5 5 3
Not assessed 2 0 1 1
IV, intravenous; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor.
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confirmed responses to therapy. One patient remained on
treatment with ongoing stable disease after more than 14
months of treatment. Seven patients had restaging of their
disease with CT scans before the protocol-defined time at the
end of cycle 2, three patients because of clinical suspicion of
progression, and four patients because intercurrent illness
prompted the earlier use of CT imaging.
Biomarker Analyses
Retrospective analysis of the EGFR-MT status and
correlation with efficacy was undertaken. Three patients were
found to have EGFR-MTs of 16 patients assessable. Median
duration on study in the EGFR-mutant group was 217 days
(range 27–245 days). Median duration of study in the 13
patients with EGFR-WT tumors was 37 days (range 21–
432). One patient remained on study (432 days), proven
to be EGFR-WT by direct sequencing.
Thirteen of 18 patients had pretreatment free IGF-1
plasma samples collected. The median PFS in the 13 of 18
patients evaluable for biomarker analysis of free-IGF-1
(fIGF-1) was 40 days, which was similar to that of the overall
trial population (39 days). Correlation of efficacy (measured
by PFS) and tolerability (using dose intensity of cixutu-
mumab as a surrogate marker) outcomes with baseline fIGF-1
indicated a nonstatistically significant trend for benefit in
terms of PFS in patients with the highest quartile of baseline
fIGF-1, but no correlation with achievable dose intensity of
TABLE 2. Adverse Events and Treatment Exposure
AE
All Patients,
All Grades
N  18
Cohort 1
Cixutumumab,
6 mg/kg q7
(N  6)
Cohort 2
Cixutumumab,
5 mg/kg q7
(N  8)
Cohort 3
Cixutumumab,
15 mg/kg q21
(N  4)
N % G1/2 G3/4 G1/2 G3/4 G1/2 G3/4
Fatigue 13 (4) 72 2 3 (3) 5 2 1 (1)
Acneiform rash 10 (3) 56 1 1 (1) 2 2 (1) 2 2 (1)
Diarrhea 9 50 2 4 3
Anorexia 5 28 2 2 1
Nausea 5 28 4 1
Dry skin 4 22 1 1 2
Mucositis 4 22 3 1
Sinusitis 4 22 3 1
Taste alteration 3 17 3
Hyperglycemia 3 17 1 2
Rigors/chills 2 11 1 1
Nail changes 2 11 1 1
Dehydration 2 11 1 1
Constipation 2 11 1 1
Nausea 2 11 2
Heartburn 2 11 2
Renal failure 2 11 1 1
Muscle cramps 2 11 2
Dizziness 2 11 2
All adverse events (AEs) are reported if more than 10%, or if grade 3 or 4. There were no grade 5 toxicities. Dose-limiting
toxicities (number of occurrences) are indicated by parenthesis.
TABLE 3. Treatment Summary
All Patients,
N  18,
N (%)
Cohort 1
Cixutumumab,
6 mg/kg, q7
(N  6)
Cohort 2
Cixutumumab,
5 mg/kg q7
(N  8)
Cohort 3
Cixutumumab,
15 mg/kg q21
(N  4)
Stable disease 5 (28) 1 4a 0
Progression 13 (72) 5b 4 4
Median PFS (d) 39 32 46 40
Range (d) 21–432 21–112 21–432 21–40
a Includes two patients with EGFR-MT.
b Includes I patient with EGFR-MT.
PFS, progression-free survival; EGFR-MT, epidermal growth factor receptor mutation.
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cixutumumab (Figure 3). There were no patients with EGFR-
MTs in the highest quartile of baseline fIGF-1. Other demo-
graphic differences between the groups are summarized in the
supplementary material (http://links.lww.com/JTO/A199).
DISCUSSION
The IGF ligand, receptor and related downstream path-
ways have been implicated as important drivers of oncogenic
growth.7 Preclinical work has demonstrated synergy with
EGFR-TKIs in both NSCLC cell lines that are both wild type
or have sensitizing mutations to EGFR-TKI therapy.10,12,13,15
Cixutumumab is an antibody directed against the IGF-1R that
has been demonstrated to be safe up to 10 mg/kg IV every 7
days and has been used at this dose in a randomized phase II
trial in conjunction with EGFR-monoclonal antibodies in
metastatic colorectal cancer with few grade 3 and 4 AEs.17
When used as a single agent, the side effects attributable
to cixutumumab have been fatigue and hyperglycemia.17,19,20
Similar AEs were reported with an alternate IGF-1R monoclonal
antibody figitumumab (Pfizer; La Jolla, CA); however, addi-
tional AEs such as increased rates of dehydration, infection, and
cardiovascular toxicity were observed when figitumumab was
combined with chemotherapy compared with chemotherapy
alone.21 In our single-arm study, the combination had a rela-
tively high level of EGFR-related side effects including acne-
iform rash and diarrhea and a significant association with grades
3 and 4 fatigue (Table 2). Interestingly, neither the randomized
trial of cixutumumab in combination with the EGFR monoclo-
nal antibody cetuximab (Imclone) nor the randomized trial of
R1507 with erlotinib reported any significant higher increased
incidence of rash or fatigue.17,22
Activity was limited with no objective responses, and 7
of 18 patients progressed before the completion of two cycles
(Table 3). The lack of benefit from the combination of this
class of antibody with erlotinib in an unselected NSCLC
population was confirmed by a recently presented random-
ized trial of the combination of erlotinib 150 mg orally daily
with an another anti-IGF-1R monoclonal antibody—R1507
(Hoffmann La Roche, Switzerland), which failed to demon-
strate an increase in response rate, PFS, or OS with the
addition of the IGF-1R monoclonal antibody to erlotinib.22 In
addition, in 2010, a press release announced that a large phase
III study (ADVIGO 1018) in nonadenocarcinoma NSCLC,
comparing full-dose erlotinib to erlotinib plus figitumumab,
was closed early after concluding that the combination was
unlikely to fulfill its primary end point of improving OS
relative to erlotinib alone. The discrepancy between preclin-
ical data demonstrating synergy and these clinical trials
maybe because of toxicity preventing achieving optimum
FIGURE 3. A, Progression-free survival and (B) dose inten-
sity of patients by baseline free IGF-1 quartiles. The middle
line of the box plots represents the median. The box repre-
sents the upper and lower quartiles, and the line extends
from the lowest to the highest PFS values. †Includes two
EGFR-MT patients and one EGFR unknown patient. IGF, insu-
lin-like growth factor; PFS, progression-free survival; EGFR-
MT, EGFR mutation.
FIGURE 2. A, Progression-free sur-
vival and (B) waterfall plot of best
response.
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dosing for synergy or the failure of preclinical models to
account for complex in vivo biological feedback loops.
In our study, although not randomized, there seemed to
be little benefit in an otherwise unselected EGFR-WT popu-
lation (median PFS 37 days). However, the patient with the
longest PFS on study (432 days) was EGFR-WT (Figure 2).
The patient was confirmed EGFR-WT by direct sequencing,
and while a missed mutation is possible, the fact that the
patient did not manifest a dramatic response per RECIST
raises the possibility that a rare and as yet undefined group
within the EGFR-WT population may be deriving particular
benefit from either or both drugs in the combination. This
patient did not have baseline free IGF-1 levels assessed. The
PFS in the EGFR-MT group was longer (median PFS 217
days) but not dramatically different from that expected from
EGFR-MT patients treated with EGFR-TKI monotherapy.5,23
In the absence of a randomized study, it is impossible to
determine whether the addition of cixutumumab was adding
or subtracting from the benefit of an EGFR-TKI alone in the
EGFR-MT population.
With regard to groups that may be deriving maximal
benefit from IGF-1R inhibitors, a previous biomarker analy-
sis within a randomized phase II study of carboplatin and
paclitaxel plus or minus figitumumab correlated increased
baseline free IGF-1 levels with the largest improvement in
PFS from the addition of figitumumab.24 A similar pattern
was also noted in the phase III study of figitumumab in
combination with carboplatin and paclitaxel in a nonadeno-
carcinoma population.21 The reason for this correlation is
unknown, but may be due to tumors that develop in patients
with high free IGF-1 developing an addiction to IGF-1
receptor signaling.24 Given the caveat of the small numbers
involved, within our study a comparable trend was also
observed, with there being a higher median PFS (83 days)
among patients within the highest quartile of free baseline
IGF-1 compared with the other quartiles (Figure 3) suggest-
ing that this may be a class effect.21,22,24 Whether free IGF-1
levels represent a biomarker for who will derive the most
benefit from such drugs in terms of a direct correlation with
activity against the tumor, or simply a marker for who it is
safest to give these agents to is currently unclear. Of note,
within our small study, there was no apparent interaction
between free IGF-1 and achievable dose intensity (as a
surrogate for overall toxicity). Either way, free IGF-1 levels
should be explored further for their potential for optimal
patient preselection for IGF-1R inhibitors in the future.
Data on the predictive value of other potential biomark-
ers, including IGFR fluorescent in situ hybridization and
silver in situ hybridization expression, and IGFR protein
expression determined by IHC were uninformative because
of the low number of patients with sufficient material for
analysis, limiting conclusions that can be made to their
relative utility in predicting benefit from the combination of
cixutumumab and erlotinib (see Supplemental Material,
http://links.lww.com/JTO/A199).
Despite promising preclinical activity, the combination
of erlotinib and cixutumumab in this trial failed to demon-
strate either the safety profile or the activity necessary to
expand the trial in unselected patients with NSCLC and
proceed to a randomized comparison to single-agent erlo-
tinib. The combination was tolerable with a dose of cixutu-
mumab at 5 mg/kg IV weekly as judged on DLT criteria, but
many patients (3/8) in this cohort still required dose reduc-
tions in the first cycle, and no patients experienced a partial
response. Although EGFR-MT patients had a longer mean
PFS than EGFR-WT patients, it is unclear, in the absence of
a randomized study, whether EGFR-MT patients are deriving
any more benefit than would be expected from exposure to an
EGFR-TKI alone. Of note, the patient with the longest PFS
on the study was EGFR-WT. Given the difficulties seen with
several other anti-IGF-1R monoclonal antibodies when com-
bined with full-dose erlotinib in NSCLC, further develop-
ment of the combination in otherwise unselected patients is
not recommended. In addition, given the negative results of a
phase III trial of an anti-IGF-1R agent used in combination
with chemotherapy in NSCLC,21 the future of these agents in
other combinations in unselected patients with NSCLC is
uncertain. However, as several studies including ours have
noted a trend toward patients with elevated baseline free
IGF-1 levels having longer PFS than those with lower lev-
els,21,22,24 this biomarker may represent a means of identify-
ing patients who will develop the most benefit from such
agents in the future.
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